Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease
暂无分享,去创建一个
[1] C. Shuman,et al. Office Guide to Diagnosis and Classification of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1993, Diabetes Care.
[2] L. Groop,et al. Clinical and Metabolic Characteristics of Type 1 and Type 2 Diabetes: An Epidemiological Study From the Närpes Community in Western Finland , 1992, Diabetic medicine : a journal of the British Diabetic Association.
[3] Å. Lernmark,et al. Islet Cell and Thyrogastric Antibodies in 633 Consecutive 15- to 34-Yr-Old Patients in the Diabetes Incidence Study in Sweden , 1992, Diabetes.
[4] M. Rowley,et al. Antibodies to Glutamic Acid Decarboxylase Discriminate Major Types of Diabetes Mellitus , 1992, Diabetes.
[5] M. Erlander,et al. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.
[6] M. Atkinson,et al. 64 000 Mr autoantibodies as predictors of insulin-dependent diabetes , 1990, The Lancet.
[7] D. Daneman,et al. Persistence of Serum Antibodies to 64,000-Mr Islet Cell Protein After Onset of Type 1 Diabetes , 1990, Diabetes.
[8] S. Baekkeskov,et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.
[9] L. Groop,et al. Organ-Specific Autoimmunity and HLA-DR Antigens as Markers for β-Cell Destruction in Patients With Type II Diabetes , 1988, Diabetes.
[10] C. de Beaufort,et al. Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. , 1987, The Journal of clinical investigation.
[11] L. Groop,et al. Islet Cell Antibodies Identify Latent Type I Diabetes in Patients Aged 35–75 Years at Diagnosis , 1986, Diabetes.
[12] D. Doniach,et al. COMPLEMENT-FIXING ISLET-CELL ANTIBODIES IN TYPE-I DIABETES: POSSIBLE MONITORS OF ACTIVE BETA-CELL DAMAGE , 1980, The Lancet.
[13] R. Prescott,et al. The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in Diabetes mellitus. , 1979, Journal of clinical & laboratory immunology.
[14] W. Irvine,et al. CLINICAL AND PATHOGENIC SIGNIFICANCE OF PANCREATIC-ISLET-CELL ANTIBODIES IN DIABETICS TREATED WITH ORAL HYPOGLYCÆMIC AGENTS , 1977, The Lancet.